Strong Performance with Significant Growth in Net Product Revenue
Innoviva ( NASDAQ:INVA ) First Quarter 2024 Results Key Financial Results Revenue: US$77.5m (up 1.5% from 1Q 2023). Net...
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.